Document Type : Original Article
Mazandaran University of Medical Sciences, Sari, Iran
Department of Infectious Diseases, Faculty of Medicin, Aja University of Medical Sciences, Tehran, Iran
Department of Pediatric Nursing, Faculty of Nursing, Aja University of Medical Sciences, Tehran, Iran
Department of Social Medicine, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran
Department of critical Nursing, Faculty of Nursing, Aja University of Medical Sciences, Tehran, Iran
Department of Trauma, Faculty of Medicin, Aja University of Medical Sciences, Tehran, Iran
Background: Present study assessed whether Sinopharm, AstraZeneca, Sputnik V, and Covaxin’s vaccinated women
reveal a distinct incidence of menstruation disturbances, hirsutism, and metrorrhagia.
Materials and Methods: Data collection was performed from June to August 2021, and 427 women working in seven
selected hospitals in Tehran were studied in this descriptive-analytical cross-sectional study. All of these women had
received one or both doses of the vaccines with one of the assessed vaccines. Required data was collected via questionnaire and imported to SPSS 16 for further assessment and analysis. Fisher’s Exact Test and Chi-Squared test were
main statistical tests used to understand whether any significant relation exists or not.
Results: The participant’s mean age and body mass index (BMI) were 29.78 ± 10.55 and 23.27 ± 3.82, respectively.
Three hundred ninety-five cases (92.4%) had received both doses of the vaccines. Also, 154 cases (36.1%) had a history
of COVID-19. A total of 38 cases (8.8%) of menstruation disturbances, 20 cases (4.6%) of metrorrhagia, and 7
cases (1.6%) of hirsutism were reported after receiving the vaccines. There was a significant difference among the
vaccinated groups with the vaccines as mentioned earlier in terms of menstruation disturbances (hypermenorrhea,
dysmenorrhea, Amenorrhea) (P=0.01). The highest and the lowest incidence of menstruation disturbances were recorded
in the group vaccinated with Covaxin (17.6%) and Sputnik V (5%), respectively. There was also no significant
difference amongst the vaccinated groups with the four vaccines regarding the incidence of metrorrhagia and
hirsutism (P=0.10 and P=0.12, respectively). There was no significant relationship between all three complications
incidence with the previous infection concerning all vaccines (coefficient=0.46, 1.27, -0.15 respectively for menstruation
disturbances, metrorrhagia, and, hirsutism).
Conclusion: Seemingly, Covaxin revealed the most side effects in terms of menstruation disturbances. As a result, professionals must carry out several studies with reasonable samples to recommend the vaccine to those women confidently.